Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T, Kusumoto M, Kato T, Kurihara Y, Sasaki S, Oikado K, Saito Y, Endo M, Fujiwara Y, Kenmotsu H, Sata M, Takano T, Kato K, Hirata K, Katagiri T, Saito H, Kuwano K.
Baba T, et al.
Int J Clin Oncol. 2023 Dec;28(12):1585-1596. doi: 10.1007/s10147-023-02414-x. Epub 2023 Oct 3.
Int J Clin Oncol. 2023.
PMID: 37787866
Free PMC article.
BACKGROUND: Interstitial lung disease/pneumonitis (ILD/pneumonitis) has been identified as a drug-related adverse event of special interest of trastuzumab deruxtecan (T-DXd), but there were a few reports of T-DXd-related ILD/pneumonitis in clinical practice. ...RESU …
BACKGROUND: Interstitial lung disease/pneumonitis (ILD/pneumonitis) has been identified as a drug-related adverse event of special interest …